Building Key Opinion Leader (KOL) relationships in Australia and New Zealand is not easy. Between balancing scientific credibility and commercial goals, rallying internal medical teams, and winning over notoriously sceptical stakeholders, it’s no wonder this challenge keeps pharma brand managers awake at night. There are smarter, simpler ways to win hearts and minds in the healthcare market.
KOL relationships in ANZ (Australia and New Zealand) can be particularly challenging due to the region’s distinct market dynamics. Pharmaceutical marketers frequently ask, “How do I motivate internal teams to prioritise KOL engagement?” This reflects a broader pain point: aligning internal stakeholders to value and support robust KOL relationships.
The aim is to foster increased KOL support for their therapies and disease area initiatives leading to better market impact.
Successfully addressing this issue can lead to enhanced brand reputation, more effective advocacy, and a stronger foundation for future launches.
Solutions tailored to ANZ
Whilst the practice of medicine in Melbourne, Florida, is quite similar to that in Melbourne, Victoria, the reality is that global examples just don’t connect in the same way and are likely to leave your target clinicians cold. Physicians are understandably cautious – they want to innovate but they don’t want to be first. Here are some ways to engage local clinicians and in time galvanise support:
These presentations should include proactive and reactive statements, disease state, product-specific details, and core clinical trial data. Tailored to the ANZ market, these presentations should reflect local nuances that resonate with stakeholders.
Hosting roundtables and multidisciplinary team meetings offers a platform for genuine dialogue. These forums enable KOLs to share insights and deepen their connections to a therapy.
Advisory boards are invaluable in providing structured environments for strategic discussions. By facilitating these sessions, you demonstrate respect for the expertise of KOLs and create opportunities for them to contribute meaningfully to your initiatives. The output of these engagements often informs brand strategy and ensures alignment with the real-world needs of healthcare providers.
Internal alignment is as crucial as external engagement. Providing your Medical Science Liaisons (MSLs) and other team members with training on KOL engagement ensures consistent and professional interactions. This investment in skills development strengthens your organisation’s overall capacity to build and sustain KOL relationships.
Doing it in practice
London Agency recently collaborated with pharmaceutical clients to strengthen relationships and help them identify more impactful ways to engage with clinicians. Many healthcare professionals (HCPs) across Australia are unaware of the novel treatments available that could benefit their patients and have instead opted for established therapies even though they may offer varying outcomes.
We developed a series of videos featuring both patients and clinicians and organised a roundtable discussion to advocate to the broader clinical community. HCPs highlighted that key decisions from the multidisciplinary team could enable on-site therapy for patients. This approach allows out of state patients to receive care closer to home, saving time and reducing financial burdens on hospitals.
The Human Element
At the core of successful KOL engagement is the understanding that these are relationships. Building trust takes time, transparency, and a genuine commitment to mutual benefit. Pharmaceutical companies that approach KOLs with authenticity and respect will see enduring partnerships and sustained advocacy.
By creating meaningful engagement opportunities, leveraging advisory boards, and aligning internal teams, pharmaceutical marketers can overcome common challenges and build lasting connections with these key stakeholders.
First published by London Agency: 29th January 2025
